Compare · BOLD vs LLY
BOLD vs LLY
Side-by-side comparison of Boundless Bio Inc. (BOLD) and Eli Lilly and Company (LLY): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BOLD and LLY operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- LLY is the larger of the two at $1.11T, about 20305.9x BOLD ($54.8M).
- Over the past year, BOLD is up 110.8% and LLY is up 48.2% - BOLD leads by 62.6 points.
- BOLD has been more active in the news (13 items in the past 4 weeks vs 8 for LLY).
- LLY has more recent analyst coverage (25 ratings vs 3 for BOLD).
- Company
- Boundless Bio Inc.
- Eli Lilly and Company
- Price
- $2.44+1.24%
- $1183.95-0.39%
- Market cap
- $54.8M
- $1.11T
- 1M return
- +76.53%
- +4.20%
- 1Y return
- +110.78%
- +48.19%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2024
- News (4w)
- 13
- 8
- Recent ratings
- 3
- 25
Eli Lilly and Company
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceuticals worldwide. It offers Baqsimi for severe hypoglycemia; Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500, and Lyumjev for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company also provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+ and HER2- metastatic breast cancer. In addition, it offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. Further, the company Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; Reyvow for migraine; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Additionally, it Bamlanivimab and etesevimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. Eli Lilly and Company has collaborations with Incyte Corporation; Pfizer Inc.; AC Immune SA; Centrexion Therapeutics Corporation; ImmuNext, Inc.; Avidity Biosciences, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; and MiNA Therapeutics Limited. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Latest BOLD
- Large owner Tang Kevin bought $222,070 worth of shares (91,585 units at $2.42) (SEC Form 4)
- Large owner Tang Kevin bought $141,865 worth of shares (57,210 units at $2.48) (SEC Form 4)
- Large owner Crandell Keith exercised 16,000 shares at a strike of $1.03 and sold $39,840 worth of shares (16,000 units at $2.49) (SEC Form 4)
- Large owner Arch Venture Fund Ix, L.P. exercised 16,000 shares at a strike of $1.03 and sold $39,840 worth of shares (16,000 units at $2.49) (SEC Form 4)
- Large owner Tang Kevin bought $268,880 worth of shares (107,463 units at $2.50) (SEC Form 4)
- SEC Form SCHEDULE 13G filed by Boundless Bio Inc.
- Large owner Tang Kevin bought $714,768 worth of shares (286,333 units at $2.50) (SEC Form 4)
- New insider Tang Kevin claimed ownership of 2,247,512 shares (SEC Form 3)
- These Emerging Companies Are Racing Toward Major Catalysts
- SEC Form 425 filed by Boundless Bio Inc.
Latest LLY
- A Nasdaq-Listed Regenerative Tissue Company Just Opened a Lab: The Next Step in Scaling a Platform Built for a NEW Aesthetics Opportunity
- Innovent Biologics and Lilly Enter into Commercialization Agreement for Verzenios® (abemaciclib) in Mainland China
- Lilly's Jaypirca (pirtobrutinib) recommended by CHMP for approval in the European Union for adults with chronic lymphocytic leukemia (CLL) across all lines of therapy
- What Medicare Part D patients need to know about accessing Foundayo (orforglipron) and Zepbound (tirzepatide) for weight management
- Lilly completes acquisition of Centessa Pharmaceuticals to advance treatments for sleep-wake disorders
- SEC Form 11-K filed by Eli Lilly and Company
- Lilly declares third-quarter 2026 dividend
- International Regulatory Pathways Have Supported Drug Development Across Biotech and Pharma
- Director Sulzberger Gabrielle was granted 4 shares, increasing direct ownership by 0.15% to 2,995 units (SEC Form 4)
- Director Luciano Juan R was granted 14 shares, increasing direct ownership by 0.08% to 16,891 units (SEC Form 4)